Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: Post hoc analysis of subgroups with and without prior disease-modifying drug treatment.

Conclusion : Post hoc evidence suggests consistent treatment benefits of cladribine tablets 3.5 mg/kg during the 96-week CLARITY study among HDA-RRMS patients who were either previously treated with DMDs or were treatment naïve. PMID: 33331183 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research